The therapeutic results in the late-stage tumour model showed that vvDD-IL-2 treatment led to a very high mortality at day 5 post-treatment (IL-2 toxicity), whereas other viruses conferred safety, and the treatments of vvDD-IL-2-FG and vvDD-IL-2-RG significantly extended the animal survival, compared to vvDD treatment. The gene discussed is IL2; the disease is neoplasm.